
What is Claimed:

1. A pharmaceutical formulation comprising a KZR-616 maleate salt, and a sugar, wherein KZR-616 has a structure , the sugar comprises trehalose, and the formulation is a lyophilized formulation, and upon reconstitution, 1.5 wt% to 3 wt% trehalose, and has a pH of 4.2.

2. The formulation of claim 1, further comprising a succinate buffer.

3. The formulation of any one of claims 1 to 2, wherein the KZR-616 is present in an amount of 100 mg/mL to 200 mg/mL based upon the weight of the KZR-616 free base.

4. The formulation of any one of claims 1 to 3, wherein the sugar further comprises mannitol.

5. The formulation of any one of claims 1 to 4, wherein the lyophilized formulation has a moisture content of less than 1%.

6. The formulation of any one of claims 1 to 5, having a pH of 4.1 to 4.3 (as measured when reconstituted) after storage at 5°C, 25°C, or 40°C for at least six months.

7. The formulation of any one of claims 1 to 6, having a reconstitution time of less than 4.5 minutes after storage at 5°C, 25°C, or 40°C for at least six months.

8. The formulation of any one of claims 1 to 7, wherein the lyophilized formulation has a moisture content of less than 1% after storage at 5°C, 25°C, or 40°C for at least six months.

9. The formulation of any one of claims 1 to 8, wherein the KZR-616 is at least 93% pure after storage at 5°C, 25°C, or 40°C for at least six months.

10. A reconstituted formulation comprising the formulation of any one of claims 1 to 9 and a solvent for reconstitution.

11. The reconstituted formulation of claim 10, wherein the solvent for reconstitution comprises water for injection (WFI) or aqueous 5% dextrose.

12. The reconstituted formulation of claim 10 or 11 having an osmolality of 275 to 325 mOsm.